Total Payments
$53,691
2024 Payments
$1,268
Companies
6
Transactions
26
Medicare Patients
324
Medicare Billing
$28,985
Payment Breakdown by Category
Research$25,528 (47.5%)
Consulting$24,083 (44.9%)
Other$2,500 (4.7%)
Travel$1,243 (2.3%)
Food & Beverage$337.96 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25,528 | 4 | 47.5% |
| Consulting Fee | $24,083 | 9 | 44.9% |
| Honoraria | $2,500 | 1 | 4.7% |
| Travel and Lodging | $1,243 | 7 | 2.3% |
| Food and Beverage | $337.96 | 5 | 0.6% |
Payments by Type
General
$28,163
22 transactions
Research
$25,528
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $32,849 | 10 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $7,287 | 6 | $0 (2018) |
| EMD Serono Research & Development Institute | $6,840 | 4 | $0 (2017) |
| Fidia Pharma USA Inc. | $2,500 | 1 | $0 (2017) |
| Eli Lilly and Company | $2,488 | 3 | $0 (2021) |
| GlaxoSmithKline, LLC. | $1,728 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,268 | 1 | GlaxoSmithKline, LLC. ($1,268) |
| 2021 | $18.00 | 1 | Eli Lilly and Company ($18.00) |
| 2020 | $4,150 | 3 | Eli Lilly and Company ($2,470) |
| 2019 | $31,629 | 10 | EMD Serono, Inc. ($31,169) |
| 2018 | $7,287 | 6 | Regeneron Pharmaceuticals, Inc. ($7,287) |
| 2017 | $9,340 | 5 | EMD Serono Research & Development Institute ($6,840) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/23/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,267.50 | General |
| 01/11/2021 | Eli Lilly and Company | — | — | In-kind items and services | $18.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | ||||||
| 09/29/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,073.00 | Research |
| Study: A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | ||||||
| 06/08/2020 | Eli Lilly and Company | — | — | In-kind items and services | $397.17 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | ||||||
| 01/06/2020 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 08/20/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $460.00 | General |
| 07/01/2019 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,960.00 | General |
| 07/01/2019 | EMD Serono, Inc. | — | Travel and Lodging | In-kind items and services | $712.53 | General |
| 05/09/2019 | EMD Serono, Inc. | — | Travel and Lodging | In-kind items and services | $47.50 | General |
| 05/08/2019 | EMD Serono, Inc. | — | Consulting Fee | In-kind items and services | $44.68 | General |
| 05/07/2019 | EMD Serono, Inc. | — | Travel and Lodging | In-kind items and services | $58.06 | General |
| 05/07/2019 | EMD Serono, Inc. | — | Travel and Lodging | In-kind items and services | $47.50 | General |
| 05/06/2019 | EMD Serono, Inc. | — | Travel and Lodging | In-kind items and services | $233.45 | General |
| 05/06/2019 | EMD Serono, Inc. | — | Consulting Fee | In-kind items and services | $25.13 | General |
| 02/11/2019 | EMD Serono, Inc. | Sprifermin (Biological) | — | Cash or cash equivalent | $23,040.00 | Research |
| Study: A Study to Investigate the Safety and Efficacy of Different Doses of Sprifermin in Participants with Osteoarthritis of the Knee FORWARD • Category: Immunology | ||||||
| 08/16/2018 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,960.00 | General |
| 08/16/2018 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $205.21 | General |
| 08/16/2018 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $44.86 | General |
| 08/16/2018 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $19.98 | General |
| 07/27/2018 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $6.58 | General |
| 07/26/2018 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.92 | General |
| 11/15/2017 | Fidia Pharma USA Inc. | Hymovis (Device) | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| Category: Osteoarthritis | ||||||
| 07/17/2017 | EMD Serono Research & Development Institute | Sprifermin (Biological) | Consulting Fee | Cash or cash equivalent | $6,480.00 | General |
| Category: Immunology | ||||||
| 07/17/2017 | EMD Serono Research & Development Institute | Sprifermin (Biological) | Food and Beverage | Cash or cash equivalent | $200.00 | General |
| Category: Immunology | ||||||
| 07/17/2017 | EMD Serono Research & Development Institute | Sprifermin (Biological) | Travel and Lodging | Cash or cash equivalent | $123.58 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Investigate the Safety and Efficacy of Different Doses of Sprifermin in Participants with Osteoarthritis of the Knee FORWARD | EMD Serono, Inc. | $23,040 | 1 |
| A PHASE 3 MULTICENTER STUDY TO EVALUATE THE LONG TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $2,073 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $415.17 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 58 | 63 | $9,573 | $4,497 |
| 2022 | 2 | 82 | 94 | $15,584 | $7,579 |
| 2021 | 3 | 81 | 95 | $17,128 | $8,896 |
| 2020 | 3 | 103 | 118 | $17,629 | $8,013 |
Total Patients
324
Total Services
370
Medicare Billing
$28,985
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 46 | 50 | $6,700 | $3,200 | 47.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 13 | $2,873 | $1,297 | 45.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 61 | $8,174 | $4,055 | 49.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 30 | 33 | $7,410 | $3,525 | 47.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 41 | 52 | $7,085 | $4,042 | 57.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 31 | $6,851 | $3,616 | 52.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $3,192 | $1,239 | 38.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 44 | 51 | $11,622 | $4,281 | 36.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 39 | 46 | $4,600 | $2,871 | 62.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 20 | 21 | $1,407 | $862.16 | 61.3% |
About Dr. Chian Kwoh, MD
Dr. Chian Kwoh, MD is a Specialist healthcare provider based in Tucson, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730153131.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chian Kwoh, MD has received a total of $53,691 in payments from pharmaceutical and medical device companies, with $1,268 received in 2024. These payments were reported across 26 transactions from 6 companies. The most common payment nature is "" ($25,528).
As a Medicare-enrolled provider, Kwoh has provided services to 324 Medicare beneficiaries, totaling 370 services with total Medicare billing of $28,985. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Rheumatology
- Location Tucson, AZ
- Active Since 02/14/2006
- Last Updated 02/01/2023
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1730153131
Products in Payments
- Sprifermin (Biological) $29,880
- Hymovis (Device) $2,500
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Tucson
Mrs. Amy Wagelie Steffen, M.d, M.D
Specialist — Payments: $643,569
Specialist $643,569
Mitzi Barmatz, M.d, M.D
Specialist — Payments: $203,498
Specialist $203,498
Paul Larson, M.d, M.D
Specialist — Payments: $156,427
Specialist $156,427
Michael Bookman, M.d, M.D
Specialist — Payments: $66,556
Specialist $66,556
Dr. Patrick Chiasson, Md, MD
Specialist — Payments: $48,401
Specialist $48,401
Kenneth Choi, Md, MD
Specialist — Payments: $46,526
Specialist $46,526